What is the real market size of the femtech market?
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
The femtech market has grown from a few hundred startups in 2015 to nearly 4,000 active ventures today.
Despite this explosion in companies, no single player controls more than 10% of the market, and funding remains concentrated among a small group of unicorns.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- Menopause represents a $131 billion unmet market opportunity, yet only 7% of femtech companies focus on this segment, making it the most underserved category despite affecting billions of women globally.
- Maven Clinic generates $2,300 revenue per enrolled member through its enterprise model, compared to just $15-50 per member for consumer-focused competitors like Ovia Health and Glow.
- Enterprise customer retention in the femtech market reaches 98% for leading platforms, demonstrating that employer-sponsored women's health benefits have become sticky workplace offerings that companies won't easily cut.
- Female-founded femtech startups raised an average of $4.6 million in 2024, exactly half the $9.2 million raised by all-male founding teams in the same sector.
- Flo Health converted approximately 7% of its 70 million monthly active users into paying subscribers, generating nearly $200 million in revenue and achieving Europe's first femtech unicorn status.
- The femtech market has grown 3.2 times in venture count but only 1.4 times in funding over the past decade, while broader digital health grew 2.6 times in funding during the same period.
- 43% of Fortune 500 companies now offer fertility benefits to employees, up from just 27% in 2020, reflecting rapid normalization of reproductive health as an employer responsibility.
- Period tracking apps alone have achieved 53.4% active user penetration in studied populations, making menstrual health one of the most successfully digitized categories in women's healthcare.
- Femtech companies produce nearly twice the volume of peer-reviewed research, clinical trials, and regulatory filings compared to other digital health companies, signaling a sector focused on clinical validation.
- Health systems now account for 23% of all femtech partnerships, surpassing pharmaceutical companies and indicating that hospitals view women's health technology as critical infrastructure rather than optional add-ons.
How do we define the femtech market?
We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women.
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.
We also use this definition when we make and update our pitch covering everything there is to know about the femtech market
In our femtech market deck, we will give you useful market maps and grids
What is the size of the femtech market in 2026?
What results can we find on the internet?
As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the femtech market size, using different definitions, scopes, and years.
We have consolidated their results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.
| Research Firm | Market Size | Year | Market Definition |
|---|---|---|---|
| Allied Market Research | $6.9B | 2023 | Technology-enabled solutions for reproductive and female-specific health needs. Closely aligned with our definition, focusing on biology-driven healthcare rather than general wellness. |
| Fortune Business Insights | $7.81B | 2024 | Technology for reproductive health, menstrual health, fertility, pregnancy, menopause, and pelvic health. Nearly identical to our scope with strong alignment on female-specific biological needs. |
| Mordor Intelligence | $8.56B | 2025 | Female-specific biological health technology excluding general wellness apps. Strong alignment with our definition, emphasizing clinical and reproductive focus. |
| Emergen Research | $22.1B | 2024 | Includes reproductive health technology plus some adjacent wellness categories. Somewhat broader than our definition but maintains focus on women's health. |
| Grand View Research | $39.29B | 2024 | Broader definition including wellness products, consumer health devices, and general women's health. Significantly wider scope than our technology-focused definition. |
| Precedence Research | $55.86B | 2024 | Very broad scope including wellness, fitness, nutrition, and general consumer products marketed to women. Much wider than our female-specific biology focus. |
| Global Market Insights | $60.2B | 2024 | Widest definition including general wellness, consumer products, and services not necessarily technology-enabled. Far broader than our scope. |
What can we conclude, then?
Research firms using definitions closely aligned with ours converge around $7 to $10 billion for 2024-2025, which we can project to approximately $8 to $11 billion for 2026 assuming steady growth.
The estimates that exceed $20 billion systematically include wellness products, general consumer health items, and services that fall outside our technology-enabled, biology-specific scope.
Based on this initial analysis, we estimate the femtech market is worth between $9 billion and $12 billion in 2026, though we will refine this estimate using bottom-up calculations.
In our femtech market deck, we have collected signals proving this market is hot right now
What if we try to make our own estimate?
We don't have to rely only on external analyses to estimate market size.
We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the femtech market.
Useful data about the femtech market
Here is some useful and reliable data we have collected, they will help us estimate the size of the femtech market:
- Approximately 2.0 billion women globally are of reproductive age, with 132 million annual births worldwide (UN World Population Prospects)
- The global IVF market is valued at $29.51 billion in 2024, with 2.5 to 5 million cycles performed annually (Precedence Research)
- Flo Health generates approximately $200 million in annual revenue with 70 million monthly active users and 5 million paid subscribers (Flo Health)
- Maven Clinic achieved $268 million in annual recurring revenue with an enterprise model charging $2,300 per enrolled member (Sacra)
- The menstrual health apps market alone totals $1.21 to $1.72 billion in 2024 globally (Grand View Research)
- Menopause supplements and over-the-counter treatments represent a $17.66 to $17.79 billion market in 2024 (Grand View Research)
- Smart fertility trackers constitute a $234.4 million market in 2024, growing at 14.6% annually (Fact.MR)
- Pelvic floor stimulation devices represent a market of $450 million to $1.5 billion in 2024 (Market Research Future)
- Total femtech venture capital funding reached $2.6 billion in 2024, representing 8.5% of digital health investment (PitchBook)
- 200 million women globally suffer from endometriosis, while 120 to 260 million are affected by PCOS (WHO)
- 43% of Fortune 500 companies now offer fertility benefits, up from 27% in 2020 (Global Market Insights)
- Breast cancer diagnostics alone represent a $4.49 to $5.48 billion market in 2024 (Grand View Research)
Method and calculation to get the size of the femtech market
We can start by looking at the digital health segment, which represents the core of technology-enabled femtech solutions.
Menstrual health apps generate $1.2 to $1.7 billion globally. Smart fertility trackers add another $234 million.
The IVF market of $29.51 billion includes clinical services, but technology-enabled fertility solutions like egg freezing platforms, at-home testing, and digital fertility clinics likely capture 10% to 15% of this spend.
This gives us approximately $3 to $4.5 billion from fertility technology alone.
Maven Clinic's $268 million ARR represents just one enterprise player in pregnancy and postpartum care.
If we assume Maven holds 15% to 20% market share in the enterprise pregnancy segment, the total addressable pregnancy technology market reaches $1.3 to $1.8 billion.
Pelvic floor devices contribute $450 million to $1.5 billion. Menopause technology remains nascent but growing rapidly.
If menopause represents 7% of femtech companies serving a $600 billion total market with $131 billion in unmet needs, technology-enabled solutions likely generate $500 million to $800 million currently.
Women's clinical tools like breast cancer AI diagnostics ($4.5 to $5.5 billion) and gynecological cancer screening ($2.8 billion) add significant value.
However, only the portions that are software-enabled and specifically designed for female biology fit our definition, likely 20% to 30% of this clinical market, or $1.5 to $2.5 billion.
Summing these segments gives us menstrual apps ($1.5 billion), fertility technology ($3.5 billion), pregnancy platforms ($1.5 billion), pelvic health devices ($1 billion), menopause tech ($650 million), and women's clinical tools ($2 billion).
This bottom-up calculation yields approximately $10.2 billion for 2026.
Sanity checks
Our $10.2 billion estimate aligns well with the $8.56 billion figure from Mordor Intelligence for 2025, assuming 15% to 18% annual growth.
Flo Health alone generates $200 million with just 7% conversion of its user base. If we assume 50 comparable digital health platforms exist globally at various scales, the digital app segment alone could reach $2 to $3 billion.
The venture capital funding of $2.6 billion in 2024 suggests healthy market activity. Typically, annual VC funding represents 20% to 30% of total market revenue in growth-stage technology sectors.
This ratio would imply an $8 to $13 billion market, which brackets our estimate nicely.
With 2 billion women of reproductive age globally and an average spending of $5 to $6 per woman annually on technology-enabled femtech solutions, we get exactly $10 to $12 billion.
This per-capita check validates our methodology from a different angle.
What's our final guess then?
Based on our analysis of both top-down research estimates and bottom-up calculations, we estimate the femtech market is worth approximately $10 billion in 2026.
This places the femtech market at roughly the same size as the global orthopedic devices market ($10.2 billion) or the dental equipment market ($9.8 billion).
The femtech market is significantly smaller than the broader digital health market ($250 billion) but larger than specialized segments like telehealth mental health platforms ($6 billion).
Our estimate sits comfortably between the narrow technology-focused definitions ($7 to $9 billion) and the broader market views that include adjacent categories ($20 billion plus).
The convergence of multiple methodologies around $10 billion gives us confidence in this figure. Research firms most aligned with our definition cluster at $8 to $9 billion for 2024-2025.
Projecting forward with 14% to 16% growth yields $10 to $11 billion for 2026, which our bottom-up calculation confirms.
In our femtech market deck, we provide the data and the context to understand it
Is the femtech market mature, competitive, fragmented?
The maturity score of the femtech market in 2026 is 35/100
The femtech market remains in an early-to-mid growth phase, having expanded from roughly 300 companies in 2015 to nearly 4,000 active ventures today.
However, 71% of startups under six years old have not reached Series A funding, indicating that most companies are still in early development stages.
Segment maturity varies dramatically across the femtech market. Period tracking and fertility apps have established proven business models with millions of active users and clear monetization paths.
In contrast, menopause technology, sexual health platforms, and autoimmune-focused solutions remain nascent with only 7% of companies targeting the largest unmet need.
The emergence of eight unicorns signals some market maturation, but no single company controls more than 10% market share.
This fragmentation, combined with the fact that most startups remain pre-Series A, places the femtech market firmly in early growth rather than mature status.
The competitiveness score of the femtech market in 2026 is 75/100
The femtech market is highly competitive with approximately 4,000 active ventures competing for customer attention, funding, and market share.
Despite this crowding, only 1,068 companies have received any venture funding, and just 275 have reached Series A or beyond.
Funding competition remains intense, with female-founded femtech startups raising half as much capital ($4.6 million) as all-male founding teams ($9.2 million) on average.
The sector has grown 3.2 times in venture count but only 1.4 times in funding over the past decade, creating a capital-constrained environment.
Enterprise customer acquisition has become particularly competitive, with health systems now representing 23% of all femtech partnerships.
Leading platforms like Maven Clinic maintain 98% enterprise retention rates, making it extremely difficult for newer entrants to displace established relationships once formed.
The fragmentation score of the femtech market in 2026 is 85/100
The femtech market exhibits extreme fragmentation with no dominant player controlling more than 10% of total market share in 2026.
Nearly 4,000 active companies compete across multiple segments including menstrual health, fertility, pregnancy, menopause, pelvic health, and clinical tools.
Even within specific categories, fragmentation persists. The menstrual health app segment alone includes Flo Health, Clue, Natural Cycles, and dozens of regional competitors.
Fertility technology spans IVF platforms, at-home testing kits, wearable trackers, and telehealth services, each with multiple providers.
Geographic fragmentation compounds category fragmentation, with North America hosting 55% of all femtech companies while Europe and Asia-Pacific develop distinct regional players.
This distribution creates local market leaders rather than global dominators, pushing the femtech market fragmentation score to 85 out of 100.
How much bigger will the femtech market be in 10 years?
What are the different forecasts for the growth rate of the femtech market?
One more time, let's check what other market research firms have to say.
| Research Firm | Annual Growth Rate | Until Year | Comment |
|---|---|---|---|
| Fortune Business Insights | 17.9% | 2032 | Focuses on technology-enabled reproductive health solutions, closely aligned with our definition. This represents the most optimistic scenario among well-aligned sources. We will use this as our high-end growth estimate. |
| Grand View Research | 16.37% | 2030 | Includes broader women's health categories beyond our scope. We need to adjust downward by 10-15% to account for general wellness inclusion. Strong growth signal for core femtech segments. |
| Global Market Insights | 16.0% | 2034 | Very broad definition including consumer products not technology-focused. Adjust downward by 20-25% for our narrower scope. Long forecast period provides useful directional signal. |
| Allied Market Research | 15.2% | 2033 | Well-aligned with our technology-enabled definition excluding general wellness. This estimate sits in our realistic middle range. We will weight this heavily in our calculation. |
| Mordor Intelligence | 14.42% | 2030 | Strong alignment with female-specific biological health technology. Represents conservative but credible growth based on current adoption trends. Good baseline for our low-end scenario. |
| Emergen Research | 12.9% | 2034 | Includes some adjacent wellness categories but maintains reproductive health focus. Adjust upward slightly for pure technology focus. Useful mid-range reference point. |
| Frost & Sullivan | 12.2-12.9% | 2025 | Most conservative definition excluding pharmaceuticals and consumer products entirely. Represents pure technology baseline but may underestimate emerging segment growth. Historical benchmark rather than forward projection. |
What can we conclude about the growth rate of the femtech market?
Research firms with definitions closely aligned to ours cluster around 14% to 18% compound annual growth rates through 2030 and beyond.
We believe a realistic growth estimate for the femtech market is 15.5% CAGR over the next decade, balancing optimistic technology adoption against conservative clinical validation timelines.
The femtech market growth rate of 15.5% CAGR exceeds the broader digital health market (12% CAGR) but trails emerging categories like AI-powered diagnostics (22% CAGR).
This positioning makes sense given that femtech combines established segments like period tracking with nascent categories like menopause technology.
At 15.5% annual growth, the femtech market would grow approximately 4.3 times larger by 2036 compared to 2026.
Starting from our $10 billion estimate for 2026, this trajectory would bring the femtech market to roughly $43 billion in ten years.
By 2030, just four years from now, the femtech market should reach approximately $17.5 billion assuming 15.5% CAGR.
This represents a 1.75x multiple over four years, which aligns with several research forecasts projecting $15 to $20 billion by 2030.
The strongest growth will likely come from previously underserved segments. Menopause technology growing at 16.54% CAGR will expand from tiny bases.
Enterprise employer benefits expanding from 43% to potentially 70% of large companies by 2030 will drive B2B2C platform revenue significantly.
Geographic expansion, particularly in Asia-Pacific at 14% to 15.5% CAGR, will contribute meaningfully to global growth as China, India, and Southeast Asia digitize women's healthcare.
However, regulatory hurdles and reimbursement challenges in these markets may temper growth compared to North American expansion.
Our 15.5% CAGR estimate assumes continued venture funding at $2 to $3 billion annually, expanding employer benefits coverage, and successful regulatory clearances for new device categories.
If funding dries up or regulatory pathways tighten, growth could slow to 12% CAGR, while breakthrough menopause or autoimmune solutions could push growth to 18% CAGR.
And if you're curious about what's happening in this really interesting market, we publish a quarterly update on the activity in the femtech market here. We also have a monthly update here.
In our femtech market deck, we dentify risks investors and builders need to be aware of
What is the projected CAGR for the femtech market?
At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the femtech market. That's also why we have made this clear summary table.
| Year | Worst Case (12% annual growth) | Realistic (15.5% annual growth) | Best Case (18% annual growth) |
|---|---|---|---|
| 2027 | $11.2B | $11.6B | $11.8B |
| 2028 | $12.5B | $13.4B | $13.9B |
| 2029 | $14.0B | $15.4B | $16.4B |
| 2030 | $15.7B | $17.8B | $19.4B |
| 2031 | $17.6B | $20.6B | $22.9B |
| 2032 | $19.7B | $23.8B | $27.0B |
| 2033 | $22.0B | $27.4B | $31.9B |
| 2034 | $24.7B | $31.7B | $37.6B |
| 2035 | $27.6B | $36.6B | $44.4B |
| 2036 | $30.9B | $42.2B | $52.4B |
What would it take for the femtech market to be worth $52 billion?
Reaching $52 billion by 2036 requires menopause technology to capture its full addressable market potential of $131 billion in currently unmet needs.
This means menopause solutions must expand from 7% of femtech companies today to 25% or more, with breakthrough treatments achieving mainstream adoption.
Employer benefits coverage must accelerate beyond current trajectories. Rather than 43% of Fortune 500 companies offering fertility benefits, we would need 80% to 90% coverage.
Menopause support, currently absent for 80% of women over 50, must become a standard employer offering reaching 60% to 70% penetration.
Asia-Pacific growth must exceed baseline projections, with China and India becoming major femtech markets rather than emerging ones.
This requires regulatory clarity, reimbursement pathways, and cultural acceptance of digital reproductive health tools progressing faster than historical technology adoption curves in these regions.
Clinical validation must drive mainstream medical adoption rather than remaining a consumer wellness category. AI-enhanced diagnostics for breast and gynecological cancers need to achieve standard-of-care status.
Pelvic floor devices must transition from specialty purchases to routine physician prescriptions covered by insurance.
Consolidation must create category-defining platforms with $1 billion plus annual revenues across multiple lifecycle stages.
Instead of fragmented point solutions, we need integrated platforms serving women from menstruation through menopause, combining telehealth, wearables, diagnostics, and treatment.
Venture funding must sustain or exceed $3 billion annually rather than cycling through boom-bust patterns. Female-founded startups need equitable access to capital.
The current $4.6 million average for female founders versus $9.2 million for male teams must narrow to parity.
Regulatory pathways, particularly FDA clearances and European CE marking, must accelerate rather than creating bottlenecks.
If 510(k) clearances average 3 to 6 months, this timeline cannot extend as more complex AI and device combinations enter the market.
The femtech market reaching $52 billion by 2036 is achievable but requires near-perfect execution across funding, regulation, clinical evidence, and employer adoption simultaneously.
In our femtech market deck, we answer all the common questions from investors and entrepreneurs
Where is the money in the femtech market?
What are the categories and how much do they generate?
Reproductive health and fertility dominate the femtech market in 2026 with approximately 44% of total revenue, generating roughly $4.4 billion from the $10 billion total.
This category benefits from established IVF infrastructure, proven app monetization through subscriptions, and rapidly expanding employer fertility benefits reaching 43% of Fortune 500 companies.
Pregnancy and postpartum solutions capture about 25% of femtech market revenue in 2026, approximately $2.5 billion.
Enterprise platforms like Maven Clinic drive significant revenue at $2,300 per enrolled member, while consumer apps and wearable pregnancy monitors contribute smaller but meaningful consumer spending.
Menstrual and cycle health represents roughly 18% of the femtech market, generating approximately $1.8 billion in 2026.
This segment includes period tracking apps like Flo Health and Natural Cycles, which have achieved strong consumer adoption with 53.4% active user penetration but face monetization challenges.
Women's clinical tools including AI diagnostics for breast and gynecological cancers contribute about 8% of femtech market revenue, roughly $800 million in 2026.
Pelvic and sexual health devices add another 4% or $400 million, while menopause technology remains nascent at just 1% despite representing the largest unmet need.
Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the femtech market as well as our list of the most valued startups.
How will it evolve?
By 2030, menopause technology should expand dramatically from 1% to approximately 8% of femtech market share as specialized platforms launch and employer benefits expand.
Fertility will decline slightly from 44% to 38% of total revenue, not from absolute decline but from faster growth in previously underserved categories.
Pregnancy and postpartum will maintain roughly 24% to 25% market share through 2030, with enterprise B2B2C models continuing to demonstrate superior unit economics.
Menstrual health will compress from 18% to 14% as the category matures and growth slows relative to emerging segments.
By 2036, we expect menopause to command 15% to 18% of the femtech market as breakthrough treatments and employer mandates drive mainstream adoption.
Fertility will stabilize around 35% of total revenue, while clinical tools expand to 12% as AI diagnostics become standard care.
Women's autoimmune and chronic condition management, currently negligible, could emerge as a 5% to 8% category by 2036 if platforms successfully address conditions disproportionately affecting women.
Pelvic and sexual health should grow to 6% to 8% of the market as stigma reduces and insurance coverage improves.
Where to spend your energy as an investor or a builder in the femtech market then?
Menopause represents the single largest white space opportunity with a $131 billion unmet market but only 7% of current femtech companies competing there.
Early movers in this category will face less competition and can establish category leadership before the segment attracts crowded venture funding.
Enterprise B2B2C models consistently outperform direct-to-consumer approaches, with Maven Clinic generating $2,300 per member versus $15 to $50 for consumer apps.
Building for employer benefits expansion rather than individual consumers offers superior unit economics and 98% retention rates that consumer models cannot match.
Clinical validation creates defensible moats that pure software solutions lack. Companies with FDA clearances, peer-reviewed research, and multi-year clinical trials command premium valuations.
Spending two years in research before launch, as successful founders recommend, pays dividends in competitive positioning and reimbursement pathways.
Platform consolidation across the female lifecycle offers more value than point solutions. Women want integrated care from menstruation through menopause rather than juggling five separate apps.
Builders should design for eventual category expansion rather than optimizing for a single life stage.
And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the femtech market here. We also analyze long-term funding trends in the femtech market here.
In our femtech market deck, we track adoption trends and shifts in consumer behavior
What is the geographical revenue breakdown for the femtech market?
North America
North America commands approximately 48% of the femtech market in 2026, generating roughly $4.8 billion from the $10 billion global total.
The United States dominates with advanced healthcare infrastructure, a mature venture capital ecosystem, and favorable FDA regulatory pathways that accelerate product launches.
By 2030, North America will likely maintain 44% to 46% market share as faster growth in Asia-Pacific and Europe gradually reduces relative dominance.
However, absolute revenue will still grow significantly as employer benefits expand and menopause solutions gain traction among the 55 million US women over age 50.
By 2036, North America should stabilize around 40% to 42% of the global femtech market despite continued absolute growth.
Saturation in employer benefits coverage and maturation of consumer adoption will slow growth relative to emerging markets, though clinical innovation will sustain leadership in high-value segments.
Europe
Europe represents approximately 28% of the femtech market in 2026, generating roughly $2.8 billion in revenue.
Germany leads as the largest European market, while the UK maintains a strong startup ecosystem supported by NHS digital health initiatives and favorable regulatory collaboration.
By 2030, Europe will expand to 30% to 32% of global femtech market share as CE marking standardization and reimbursement policies mature.
Germany's 2023 Digital Health Reimbursement Law, which achieved 63% uptake for menopause programs, provides a template for broader European adoption.
By 2036, Europe should command 32% to 34% of the femtech market as it closes the gap with North America in employer benefits and digital health adoption.
The region holds 38% of the global IVF market share, suggesting fertility technology will drive substantial growth as other segments catch up.
Asia-Pacific
Asia-Pacific accounts for approximately 15% of the femtech market in 2026, generating roughly $1.5 billion despite representing the fastest-growing region globally.
China leads with startups like Babytree and Meiyou, while India focuses on mobile-first solutions and Japan drives wearables innovation.
By 2030, Asia-Pacific will expand to 18% to 20% of global femtech market share as smartphone penetration deepens and digital health acceptance grows.
The region holds 39.2% of the global infertility treatment market, indicating strong underlying demand that technology platforms can capture.
By 2036, Asia-Pacific should reach 22% to 25% of the femtech market as China, India, and Southeast Asia establish mature digital health ecosystems.
Regulatory clarity and reimbursement pathways must improve significantly for this growth to materialize, but demographic trends and smartphone ubiquity create favorable conditions.
Latin America
Latin America represents approximately 6% of the femtech market in 2026, generating roughly $600 million led by Brazil and Mexico.
The Feel and Lilit merger in 2022 signals regional consolidation, while startups like Mamotest focus on expanding breast cancer screening access.
By 2030, Latin America will grow to 7% to 8% of global femtech market share as 82% healthcare facility ICT adoption enables digital health scaling.
Mobile-first solutions designed for lower smartphone specifications and intermittent connectivity will drive growth in this region.
By 2036, Latin America should stabilize around 8% to 9% of the femtech market with strong growth in Brazil, Mexico, and Argentina.
Economic volatility and healthcare funding constraints will limit faster expansion, but large reproductive-age populations create substantial addressable markets.
Middle East and Africa
Middle East and Africa combined account for approximately 3% of the femtech market in 2026, generating roughly $300 million across diverse markets.
The UAE and Saudi Arabia lead through government digital health initiatives, while Israel has emerged as a significant innovation hub with specialized femtech intellectual property programs.
By 2030, this region will expand to 4% to 5% of global femtech market share as mobile-first solutions address maternal health and menstrual hygiene education.
Grace Health's SMS-based menstrual tracking launched in Nigeria in 2024 demonstrates the potential for accessible, low-tech solutions in African markets.
By 2036, Middle East and Africa should reach 6% to 7% of the femtech market as Gulf states invest heavily in healthcare technology infrastructure.
Sub-Saharan Africa will remain constrained by connectivity and affordability challenges, but targeted maternal health solutions could achieve meaningful scale.
In our femtech market deck, we have designed useful charts to give you full market clarity
Related blog posts
- The most recent news in the femtech market
- Which companies are the most valued in the femtech market?
- The latest developments in the femtech market
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- Which companies have raised the most funding in the femtech market?
